Patents by Inventor Alain Prochiantz

Alain Prochiantz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Ligand controling interaction between gags with their effector molecules and use thereof
    Patent number: 11357816
    Abstract: The invention relates to new compounds that mimic Glycosaminoglycans and are able to control interaction between Glycosaminoglycans with their effector molecules. The compounds of the invention are peptides and are able to prevent or reduce the binding of at least one effector molecule with at least one glycosaminoglycan. The compounds according to the invention can be used as drug, in particular for the stimulation of the neurogenesis and more generally to treat nervous system related pathologies.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: June 14, 2022
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), SORBONNE UNIVERSITE, ECOLE NORMALE SUPERIEURE, COLLEGE DE FRANCE
    Inventors: Jean-Maurice Mallet, Solange Lavielle, Rodrigue Marquant, Alain Prochiantz, Ariel Di Nardo, Damien Testa
  • HOMEOPROTEINS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS
    Publication number: 20210379144
    Abstract: The present disclosure relates to the use of a homeoprotein or a recombinant vector encoding said protein for treating or preventing DNA damage and/or cellular aging. In particular, the invention concerns the use of Engrailed for the treatment of Parkinson disease.
    Type: Application
    Filed: June 16, 2021
    Publication date: December 9, 2021
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), COLLEGE DE FRANCE, SORBONNE UNIVERSITE
    Inventor: Alain Prochiantz
  • LIGAND CONTROLING INTERACTION BETWEEN GAGS WITH THEIR EFFECTOR MOLECULES AND USE THEREOF
    Publication number: 20210252101
    Abstract: The invention relates to new compounds that mimic Glycosaminoglycans and are able to control interaction between Glycosaminoglycans with their effector molecules. The compounds of the invention are peptides and are able to prevent or reduce the binding of at least one effector molecule with at least one glycosaminoglycan. The compounds according to the invention can be used as drug, in particular for the stimulation of the neurogenesis and more generally to treat nervous system related pathologies.
    Type: Application
    Filed: June 17, 2019
    Publication date: August 19, 2021
    Inventors: Jean-Maurice MALLET, Solange LAVIELLE, Rodrigue MARQUANT, Alain PROCHIANTZ, Ariel DI NARDO, Damien TESTA
  • Methods of delivering a polypeptide molecule to Otx2 target cells using an Otx2 targeting peptide
    Patent number: 10842852
    Abstract: The disclosure provides a method of delivering a polypeptide molecule to an Otx2 target cell, including contacting the target cell with a chimeric polypeptide having (i) a targeting peptide consisting of SEQ ID NO: 2 and (ii) the polypeptide molecule.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: November 24, 2020
    Assignees: Centre National de la Recherche Scientifique, Ecole Normale Superieure
    Inventors: Alain Prochiantz, Ariel Di Nardo, Marine Beurdeley, Takao Hensch
  • Methods of reducing excitotoxicity-induced retinal ganglionic neuron degeneration by an orthodenticle HOMOLOG2 (OTX2) homeoprotein
    Patent number: 10722554
    Abstract: The invention relates to the use of a homeoprotein of the bicoid family, in particular of the Otx family, for enhancing the survival of cultivated retinal ganglion neurones, and for preventing or treating ganglion neuron degeneration particularly occurring in glaucoma.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: July 28, 2020
    Assignees: Centre National de la Recherche Scientifique, Ecole Normale Superieure
    Inventors: Alain Prochiantz, Kenneth Lee Moya
  • HOMEOPROTEINS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS
    Publication number: 20190247461
    Abstract: The present invention relates to the use of a homeoprotein or a recombinant vector encoding said protein for treating or preventing DNA damage and/or cellular aging. In particular, the invention concerns the use of Engrailed for the treatment of Parkinson disease.
    Type: Application
    Filed: September 23, 2016
    Publication date: August 15, 2019
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), COLLEGE DE FRANCE, SORBONNE UNIVERSITE
    Inventor: Alain Prochiantz
  • Use of engrailed proteins for increasing dopamine synthesis by dopaminergic neurons
    Patent number: 10342851
    Abstract: The invention relates to the use of an Engrailed protein as a medicament for increasing dopamine synthesis by dopaminergic neurons, in particular in the management of conditions associated with a decrease of dopamine levels without loss of dopaminergic neurons.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: July 9, 2019
    Assignees: Centre National de la Recherche Scientifique, College de France
    Inventors: Alain Prochiantz, Kenneth Moya, Rajiv Joshi
  • Use of a reverse-transcriptase inhibitor in the prevention and treatment of degenerative diseases
    Patent number: 10100307
    Abstract: The invention relates to the use of a reverse-transcriptase inhibitor in the prevention or treatment of a degenerative disease.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: October 16, 2018
    Assignees: Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale (INSERM), College de France, Sorbonne Universite
    Inventors: Alain Prochiantz, Julia Fuchs, Rajiv Joshi, François Xavier Blaudin De The, Hocine Rekaik, Olivia Massiani-Beaudoin
  • Use of Engrailed Proteins for Increasing Dopamine Synthesis by Dopaminergic Neurons
    Publication number: 20180271937
    Abstract: The invention relates to the use of an Engrailed protein as a medicament for increasing dopamine synthesis by dopaminergic neurons, in particular in the management of conditions associated with a decrease of dopamine levels without loss of dopaminergic neurons.
    Type: Application
    Filed: March 16, 2018
    Publication date: September 27, 2018
    Applicants: Centre National de la Recherche Scientifique, College de France
    Inventors: Alain Prochiantz, Kenneth Moya, Rajiv Joshi
  • INHIBITION OF THE SYNTHESIS OF BETA-APP OR OF THE ACTIVITY OF THE A-BETA PEPTIDE IN THE CHOROID PLEXUS
    Publication number: 20180142012
    Abstract: The invention relates to the treatment of neurodegenerative diseases, in particular Alzheimer's disease, by inhibition of the synthesis of ?APP or of the activity of the A? peptide in the choroid plexus.
    Type: Application
    Filed: December 4, 2017
    Publication date: May 24, 2018
    Applicants: Centre National de la Recherche Scientifique, Collège de France, Institut National de la Santé et de la Recherche Médicale (INSERM)
    Inventors: Ariel Di Nardo, Kenneth Lee Moya, Karen Arnaud, Alain Prochiantz
  • Use of engrailed proteins for increasing dopamine synthesis by dopaminergic neurons
    Patent number: 9950033
    Abstract: The invention relates to the use of an Engrailed protein as a medicament for increasing dopamine synthesis by dopaminergic neurons, in particular in the management of conditions associated with a decrease of dopamine levels without loss of dopaminergic neurons.
    Type: Grant
    Filed: February 29, 2012
    Date of Patent: April 24, 2018
    Assignees: Centre National de la Recherche Scientifique, College de France
    Inventors: Alain Prochiantz, Kenneth Moya, Rajiv Joshi
  • Inhibition of the synthesis of beta-app or the activity of the A-? peptide in the choroid plexus
    Patent number: 9868783
    Abstract: The invention relates to the treatment of neurodegenerative diseases, in particular Alzheimer's disease, by inhibition of the synthesis of ?APP or of the activity of the A? peptide in the choroid plexus.
    Type: Grant
    Filed: July 4, 2014
    Date of Patent: January 16, 2018
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, COLLEGE DE FRANCE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Ariel Di Nardo, Kenneth Lee Moya, Karen Arnaud, Alain Prochiantz
  • Use of a Reverse-Transcriptase Inhibitor in the Prevention and Treatment of Degenerative Diseases
    Publication number: 20170335320
    Abstract: The invention relates to the use of a reverse-transcriptase inhibitor in the prevention or treatment of a degenerative disease.
    Type: Application
    Filed: October 30, 2015
    Publication date: November 23, 2017
    Inventors: Alain Prochiantz, Julia Fuchs, Rajiv Joshi, François Xavier Blaudin De The, Hocine Rekaik, Olivia Massiani-Beaudoin
  • Polypeptides for Specific Targeting to Otx2 Target Cells
    Publication number: 20170080060
    Abstract: The disclosure provides a method of delivering a polypeptide molecule to an Otx2 target cell, including contacting the target cell with a chimeric polypeptide having (i) a targeting peptide consisting of SEQ ID NO: 2 and (ii) the polypeptide molecule.
    Type: Application
    Filed: September 29, 2016
    Publication date: March 23, 2017
    Applicants: Centre National de la Recherche Scientifique, Ecole Normale Superieure
    Inventors: Alain Prochiantz, Ariel Di Nardo, Marine Beurdeley
  • INHIBITION OF THE SYNTHESIS OF BETA-APP OR OF THE ACTIVITY OF THE A-BETA PEPTIDE IN THE CHOROID PLEXUS
    Publication number: 20160159889
    Abstract: The invention relates to the treatment of neurodegenerative diseases, in particular Alzheimer's disease, by inhibition of the synthesis of ?APP or of the activity of the A? peptide in the choroid plexus.
    Type: Application
    Filed: July 4, 2014
    Publication date: June 9, 2016
    Applicants: Centre National de la Recherche Scientifique, Collège de France, Institut National de la Santé et de la Recherche Médicale (INSERM)
    Inventors: Ariel Di Nardo, Kenneth Lee Moya, Karen Arnaud, Alain Prochiantz
  • Use of Engrailed Proteins for Increasing Dopamine Synthesis by Dopaminergic Neurons
    Publication number: 20150057231
    Abstract: The invention relates to the use of an Engrailed protein as a medicament for increasing dopamine synthesis by dopaminergic neurons, in particular in the management of conditions associated with a decrease of dopamine levels without loss of dopaminergic neurons
    Type: Application
    Filed: February 29, 2012
    Publication date: February 26, 2015
    Applicants: COLLEGE DE FRANCE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Alain Prochiantz, Kenneth Moya, Rajiv Joshi
  • Use of the engrailed homeodomain protein as anxiolytic
    Patent number: 8575105
    Abstract: The present invention relates to the use of an Engrailed transcription factor for producing a medicament for anxiolytic purposes.
    Type: Grant
    Filed: February 28, 2007
    Date of Patent: November 5, 2013
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Alain Prochiantz, Michel Volovitch
  • Carrier vectors through an epithelium with tight junctions
    Patent number: 8242088
    Abstract: The invention concerns peptide vectors, comprising a transduction domain, and a nuclear export sequence, for carrying a molecule of interest through an epithelium with tight junctions, such as the blood-brain barrier.
    Type: Grant
    Filed: November 20, 2001
    Date of Patent: August 14, 2012
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Alain Joliot, Edmond Dupont, Alain Prochiantz
  • Polypeptides for Specific Targeting to Otx2 Target Cells
    Publication number: 20120015884
    Abstract: The invention relates to polypeptides which enable the specific targeting of a molecule of interest to homeoprotein Otx2 target cells. These polypeptides are defined by the general sequence: B1B2X1B3B4X2B5X3X4X5X6B6X7X8X9 (SEQ ID NO: 1), in which: B1, B2, B3, B4, B5 and B6are independently arginine or lysine; X1 and X8 are independently asparagine or glutamine; X2 is aspartic acid or glutamic acid; X3, X4 and X6 are independently threonine or serine; X5 is phenylalanine, tyrosine or tryptophan; X7 represents alanine or glycine; X9 is leucine, isoleucine or valine.
    Type: Application
    Filed: January 19, 2010
    Publication date: January 19, 2012
    Inventors: Alain Prochiantz, Ariel Di Nardo, Marine Beurdeley
  • USE OF THE ENGRAILED HOMEODOMAIN PROTEIN AS ANXIOLYTIC
    Publication number: 20110294739
    Abstract: The present invention relates to the use of an Engrailed transcription factor for producing a medicament for anxiolytic purposes.
    Type: Application
    Filed: February 28, 2007
    Publication date: December 1, 2011
    Inventors: Alain Prochiantz, Michel Volovitch